Alnylam Pharmaceuticals, Inc. ALNY
Composite 58/100; the shares have moved about 57% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 21/100 — a strong mark against it.
Growth ranks 96/100 — a strong point in its favour. Quality ranks 78/100 — a strong point in its favour. Balance-sheet strength ranks 68/100 — a moderate point in its favour.
Momentum ranks 21/100 — a strong mark against it. Valuation ranks 23/100 — a strong mark against it.
What the company does Alnylam Pharmaceuticals (ALNY) discovers and commercializes RNAi-based therapeutics for rare diseases and chronic conditions. Its marketed drugs include ONPATTRO, AMVUTTRA, and Leqvio, with a deep late-stage pipeline targeting ATTR amyloidosis, hypertension, and metabolic disorders.
Key financials ALNY reports gross margins of 80.8%, operating margins of 23.0%, and net margins of 12.6%. ROE is 90.4%, ROA 10.1%, and ROCE 23.0%. Revenue grew 96.4% year-over-year, while EPS growth was 0.0%. The balance sheet shows a debt/equity of 2.76 and a current ratio of 3.13.
Stock health The stock is down -58.53% from its 52-week high and has a beta of 0.27. Momentum metrics are weak: -31.78% over 3 months, -41.22% over 6 months, and RSI(14) at 23.50. Analysts highlight high valuation risk despite strong fundamentals.
Price vs fair value ALNY trades at a PREMIUM of 54.00% versus our fair-value estimate of 94.62 and at a discount of 108.10% versus the analyst 12-month target of 427.61. - Q2 2026 earnings missed revenue and EPS estimates (Zacks) - "One-two punch" cited as driving a sharp sell-off (BioPharma Dive) - Amvuttra revenue exceeded $1B but outlook tempered (GuruFocus.com) - Forward P/E of 32.57 remains elevated vs peers (Valuation percentile 18.2)
Looking forward The pipeline remains robust with multiple Phase 3 candidates, but near-term sentiment is pressured by execution risk and valuation. Analysts (n=23) see 108.10% upside to 427.61, though the stock’s premium to fair value (54.00%) reflects high expectations.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.